NHD Global
Metabolic & Weight Loss · Growth-hormone fragment research
Scientific Product Dossier
AOD-9604 is a modified growth-hormone fragment investigated for obesity. FDA’s 2024 review records that the 536-participant OPTIONS study did not produce statistically significant weight loss versus placebo at 12 or 24 weeks, and the sponsor terminated development for obesity. The key large study was not published as a complete medical-journal trial report.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
The 536-participant program did not show statistically significant weight loss versus placebo at the 12- or 24-week endpoints.
FDA reported that the obesity development program was terminated.
Read the primary studyFDA could not locate a complete medical-journal publication containing the study methods and detailed efficacy results.
Regulatory and sponsor records are therefore central to the evidence map.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 2 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
U.S. FDA Pharmacy Compounding Advisory Committee. OPTIONS effectiveness and safety review.
View primary recordWilding J. Current Opinion in Investigational Drugs. 2004. PMID 15134286.
View primary recordThird-party publications selected for direct relevance.
U.S. FDA. December 4, 2024 Pharmacy Compounding Advisory Committee briefing document.
Wilding J. Current Opinion in Investigational Drugs. 2004. PMID 15134286.
Concise answers for researchers comparing identity, evidence and catalog variants.
No. FDA’s review states that weight loss versus placebo at 12 and 24 weeks was too small to reach statistical significance.
Without a complete journal report, methods, missing-data handling and detailed analyses cannot be independently inspected in the usual way.
Family-level identifiers organize the catalog, while the applicable product specification and lot-specific COA control the supplied form, identity and release results.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
AOD-9604 progressed beyond animal work into an obesity-development program. FDA’s 2024 review records that the large OPTIONS study did not show statistically significant weight…
Updated September 1, 2026
AOD-9604 is a modified growth-hormone fragment developed around a lipolysis hypothesis. Preclinical plausibility and early development do not override the larger null obesity trial.
Updated August 28, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: AOD2 · 2 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
